Studies in hepatocellular carcinoma (HCC) demonstrated the number of infiltrating CD8+ T cells and the fraction of activated CD8+ T cells is significantly increased after the combination therapy (Xiao et al., 2022). Here, CD8A is linked to hepatocellular carcinoma.